Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Human Polyclonal RIPK2 Primary Antibody for IHC (p), WB - ABIN1881750
Cirulli, Kasperaviciūte, Attix, Need, Ge, Gibson, Goldstein: Common genetic variation and performance on standardized cognitive tests. in European journal of human genetics : EJHG 2010
Show all 3 Pubmed References
Human Monoclonal RIPK2 Primary Antibody for WB - ABIN4350595
Lu, Wang, Dorsch, Tian, Nagashima, Coyle, Jaffee, Ocain, Xu: Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. in The Journal of biological chemistry 2005
Show all 2 Pubmed References
Human Monoclonal RIPK2 Primary Antibody for IHC (p), ELISA - ABIN522206
Yan, Liu: LRRK2 enhances Nod1/2-mediated inflammatory cytokine production by promoting Rip2 phosphorylation. in Protein & cell 2016
Human Monoclonal RIPK2 Primary Antibody for IHC (p), ELISA - ABIN563776
Eisenhardt, Habersberger, Oliva, Lancaster, Ayhan, Woollard, Bannasch, Rice, Peter: A proteomic analysis of C-reactive protein stimulated THP-1 monocytes. in Proteome science 2011
RIP2 (show ARHGDIG Antibodies)-knockout attenuates cardiac injury and dysfunction in hypertrophic heart. RIP2 (show ARHGDIG Antibodies)-deficience alleviates inflammation in heart of hypertrophic mice. RIP2 (show ARHGDIG Antibodies)-deletion inhibits fibrosis in the heart of hypertrophic mice.
this study reveals that LRRK2 is a new positive regulator of Rip2 (show ARHGDIG Antibodies) and promotes inflammatory cytokine induction through the Nod1 (show NOD1 Antibodies)/2-Rip2 (show ARHGDIG Antibodies) pathway.
that Rip2 (show ARHGDIG Antibodies) modifies VEGF (show VEGFA Antibodies)-induced signalling and vascular permeability in myocardial ischaemia
Bacterial polysaccharide-responsive miR (show MLXIP Antibodies)-150 and miR (show MLXIP Antibodies)-143 RIPK2 and TAK1 (show NR2C2 Antibodies) to suppress NOD2 (show NOD2 Antibodies)-induced immunomodulators.
NOD2 (show NOD2 Antibodies) downregulates colonic inflammation by IRF4 (show IRF4 Antibodies)-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6 (show TRAF6 Antibodies).
RIPK2 has a role in NOD signalling and in inflammatory cytokine production
Rip2 (show ARHGDIG Antibodies)-deficient tumors showed enhanced epithelial-to-mesenchymal transition, with elevated expression of zeb1 (show ZEB1 Antibodies), zeb2 (show ZEB2 Antibodies), twist, and snail (show SNAI1 Antibodies) in the tumor microenvironment.
data show that Nod1 (show NOD1 Antibodies), Nod2 (show NOD2 Antibodies) and Rip2 (show ARHGDIG Antibodies) are not required for local chemokine (show CCL1 Antibodies) production and neutrophil recruitment during CLP (show HAPLN1 Antibodies)-induced sepsis, and they reinforce the importance of MyD88 (show MYD88 Antibodies)-dependent signaling for initiation of a protective host response.
Suggest that the Nod2 (show NOD2 Antibodies)-Rip2 (show ARHGDIG Antibodies) axis may contribute to the innate immune response of neutrophils against bacterial infection.
Nod/Ripk2 signaling in dendritic cells activates IL-17A (show IL17A Antibodies)-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2 (show RAG2 Antibodies)-/- (TRUC) mice.
Together, these data show that RIP2 (show ARHGEF28 Antibodies) promotes survival of breast cancer cells through NF-kappaB (show NFKB1 Antibodies) activation and that targeting RIP2 (show ARHGEF28 Antibodies) may be therapeutically beneficial for treatment of TNBC.
RIP2 (show ARHGEF28 Antibodies) kinase auto-phosphorylation is intimately coupled to dimerization.
study provides structural and dynamic insights into the NOD1 (show NOD1 Antibodies)-RIP2 (show ARHGEF28 Antibodies) oligomer formation, which will be crucial in understanding the molecular basis of NOD1 (show NOD1 Antibodies)-mediated CARD-CARD interaction in higher and lower eukaryotes
a new function of PAX5 (show PAX5 Antibodies) in regulating RIP1 (show UQCRFS1 Antibodies) and RIP2 (show ARHGEF28 Antibodies) activation, which is at least involved in chemotherapeutic drug resistance in B-lymphoproliferative disorders, is reported.
this study reveals that LRRK2 is a new positive regulator of Rip2 (show ARHGEF28 Antibodies) and promotes inflammatory cytokine induction through the Nod1 (show NOD1 Antibodies)/2-Rip2 (show ARHGEF28 Antibodies) pathway.
Together, the data demonstrate that the NOD2 (show NOD2 Antibodies)-RIP2 (show ARHGEF28 Antibodies) pathway is activated in murine and human visceral leishmaniasis and plays a role in shaping adaptive immunity toward a Th1 (show TH1L Antibodies) profile.
RIP2 (show ARHGEF28 Antibodies) and RhoGDI (show ARHGDIA Antibodies) bind to p75(NTR (show NGFR Antibodies)) death domain at partially overlapping epitopes with over 100-fold difference in affinity, revealing the mechanism by which RIP2 (show ARHGEF28 Antibodies) recruitment displaces RhoGDI (show ARHGDIA Antibodies) upon ligand binding.
that Rip2 (show ARHGEF28 Antibodies) modifies VEGF (show VEGFA Antibodies)-induced signalling and vascular permeability in myocardial ischaemia
Barettin has inhibitory activity against two protein kinases related to inflammation, namely the receptor-interacting serine/threonine kinase 2 (RIPK2) and calcium/calmodulin-dependent protein kinase (show CAMK2 Antibodies) 1alpha (CAMK1alpha).
RIPK1 (show RIPK1 Antibodies) and RIPK2 are targets of HIV-1 Protease activity during infection, and their inactivation may contribute to modulation of cell death and host defense pathways by HIV-1
SNPs and haplotypes from RIPK2 were associated with tick burden in both dairy and beef cattle.
Genetic mapping of RIPK2 in cattle.
This gene encodes a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases. The encoded protein contains a C-terminal caspase activation and recruitment domain (CARD), and is a component of signaling complexes in both the innate and adaptive immune pathways. It is a potent activator of NF-kappaB and inducer of apoptosis in response to various stimuli.
receptor-interacting serine-threonine kinase 2
, receptor-interacting serine/threonine-protein kinase 2-like
, receptor-interacting serine/threonine-protein kinase 2
, tyrosine-protein kinase RIPK2
, CARD-carrying kinase
, CARD-containing IL-1 beta ICE-kinase
, CARD-containing interleukin-1 beta-converting enzyme (ICE)-associated kinase
, growth-inhibiting gene 30
, receptor-interacting protein (RIP)-like interacting caspase-like apoptosis regulatory protein (CLARP) kinase
, receptor-interacting protein 2
, receptor (TNFRSF)-interacting serine-threonine kinase 2